-
HyperScribe™ T7 High Yield RNA Synthesis Kit
2026-09-20
This scenario-driven guide explains how HyperScribe™ T7 High Yield RNA Synthesis Kit, SKU K1047, can standardize RNA inputs for cell viability, proliferation, and cytotoxicity workflows. It covers template compatibility, modified RNA production, protocol controls, interpretation of metabolic readouts, and practical vendor-selection criteria.
-
Temozolomide Workflows for ATRX-Aware Glioma Research
2026-09-19
Temozolomide is more than a generic cytotoxicity reagent: it enables controlled DNA damage, DNA repair mechanism research, and ATRX-aware glioma experiments. This practical guide covers solution handling, dose-response design, combination testing with RTK or PDGFR inhibitors, and troubleshooting for chemotherapy resistance studies.
-
Shaped ABC Bottlebrush Terpolymers and Gyroid Suppression
2026-09-18
Rodriguez, Mahanthappa, and Lodge used precisely synthesized ABC coil–bottlebrush–bottlebrush terpolymers to test how brush shape influences network-phase formation. SAXS showed robust segregation but predominantly hexagonal and lamellar structures, with shaped architectures—especially those containing the longer P9 block—systematically suppressing double-gyroid formation and exhibiting unexpectedly slow ordering.
-
Dacarbazine Workflows for Cancer DNA Damage Studies
2026-09-18
Build reproducible Dacarbazine experiments around fresh preparation, exposure timing, metabolic activation, and orthogonal DNA-damage readouts. The workflow also connects tumor-cell assays with clinically relevant chemotherapy-supportive-care questions without confusing antiemetic outcomes with direct cytotoxicity.
-
Shaped Coil–Bottlebrush Terpolymers and Gyroid Suppression
2026-09-17
Rodriguez, Mahanthappa, and Lodge examine how digitally shaped bottlebrush segments alter the self-assembly of ABC coil–brush–brush terpolymers. Their SAXS results show that the architecture favors hexagonal and lamellar morphologies while systematically suppressing double-gyroid formation, even when compositions and low glass-transition temperatures might otherwise appear favorable.
-
NIH/3T3 Cells: Recovery and QC Guide
2026-09-17
NIH/3T3 Cells (BC1017) provide a cryopreserved, adherent mouse fibroblast starting material for controlled culture, cell transfection studies, viral proliferation research, and oncogene research. This guide covers recovery, expansion, assay preparation, and quality control, while clarifying that the product is for research use only and is not established for diagnostic, therapeutic, or clinical applications.
-
JNJ-10198409: A Temporal PDGF Assay Strategy
2026-09-16
JNJ-10198409 is a platelet-derived growth factor receptor inhibitor suited to mechanistic studies of signaling, proliferation, and angiogenesis. This article presents a time-resolved assay strategy inspired by host-pathogen signaling research, helping investigators distinguish receptor-proximal effects from downstream phenotypes.
-
CAF EV lncRNA Drives Immune Evasion in Pancreatic Cancer
2026-09-16
The reference study identifies CAF-derived extracellular vesicle cargo as an active regulator of immune escape in pancreatic ductal adenocarcinoma. It defines an RP11-161H23.5/CNOT4/HLA-A pathway and evaluates engineered extracellular vesicles carrying siRNAs as a potential strategy for restoring antigen-presentation capacity.
-
HDAC8, AKT, and Resistance to MEK Inhibition
2026-09-15
The reference study identifies an HDAC8-dependent escape route in cells that become resistant to MEK1/2 inhibition: PLCB1 is increased, DESC1 is suppressed, and AKT becomes activated. Its combination of microarray profiling, qPCR, pharmacological inhibition, RNA interference, and expression rescue experiments supports PLCB1 and DESC1 as mechanistically relevant targets for restoring sensitivity to MEK1/2-directed treatment.
-
(-)-JQ1 Workflows for BET Assay Specificity
2026-09-15
Use (-)-JQ1 as a stereochemistry-matched negative control to separate BET-dependent biology from solvent, scaffold, and assay-specific effects. This guide translates pancreatic cancer screening findings into practical cell-based workflows, combination studies, and troubleshooting strategies for epigenetics research.
-
ECL Western Blotting Substrate: Practical Guide
2026-09-14
ECL Western Blotting Substrate (SKU K2187) is a luminol-based, nonradioactive horseradish peroxidase detection reagent for chemiluminescent immunoblots. It is intended for HRP-based Western blot imaging with X-ray film or CCD cameras, not for fluorescent or radioisotopic detection workflows.
-
HyperScribe T7 High Yield RNA Synthesis Kit
2026-09-14
The HyperScribe T7 High Yield RNA Synthesis Kit supports high-yield T7 RNA polymerase transcription for research RNA production. A standard 20 μL reaction can produce up to approximately 50 μg of RNA with 1 μg of control template, while the kit also supports capped, dye-labeled, biotinylated, and modified RNA workflows.
-
Spleen-Targeted mRNA Vaccine Builds TLS Immunity in HCC
2026-09-13
Lin et al. developed a spleen-targeted neoantigen mRNA vaccine that generated ISG15-positive CD8-positive T cells, promoted tertiary lymphoid structure formation, and produced strong antitumor activity in orthotopic hepatocellular carcinoma models. The study links organ-selective delivery with GZMA–F2R signaling, providing a mechanistic framework for improving personalized RNA vaccine design while highlighting the need to distinguish vaccine production from delivery and biological validation.
-
Mitomycin C: DNA Damage for Assay Design
2026-09-12
Mitomycin C is an antitumor antibiotic that links DNA replication inhibition to apoptosis sensitization. This guide combines mechanistic interpretation with assay-design lessons from a CRISPR antiviral study to improve cancer research controls and reproducibility.
-
D-Luciferin and the Next Era of Glioma Imaging
2026-09-11
A translational perspective on using D-Luciferin potassium salt and in vivo bioluminescence imaging to strengthen mechanistic validation of glioma stem cell-targeted therapies, while accounting for ATP dependence, substrate delivery, and preclinical limitations.